Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Renalytix convenes expert panel at VA Healthcare Summit » 08:20
11/10/21
11/10
08:20
11/10/21
08:20
RNLX

Renalytix

$23.22 /

+0.57 (+2.52%)

Renalytix convened a…

Renalytix convened a multidisciplinary panel to discuss advances in kidney health through early-stage prognosis and intervention of chronic kidney disease, CKD, in patients with type 2 diabetes. Clinical experts shared patient case studies drawing from their experience adding KidneyIntelX into clinical care. The KidneyIntelX enabled care pathway being implemented in the Mount Sinai Health System is a model that can be used in implementing the new Veterans Health Administration CKD Directive and joint VA and Department of Defense guideline, driving care earlier to prevent progression and kidney failure. The panel event took place at The Institute for Defense and Government Advancement VA Healthcare Summit on Wednesday, October 27, 2021. The panel, "Breakthrough Diagnostic Approach for Type 2 Diabetes and Early-Stage Chronic Kidney Disease: Today's Precise Answer, Tomorrow's Kidney Health." Michael Donovan, PhD, MD, Chief Medical Officer at Renalytix: "This roundtable discussion provided a unique opportunity for clinical experts to highlight the impact of KidneyIntelX risk assessment on patient-specific management decisions. Their remarks highlighted how KidneyIntelX testing can help address the challenges they face when relying on current clinical tools. The panel also reviewed the practice-changing evidence from recent therapeutic trials. The discussion underscored the importance of a systems approach to managing care for chronic kidney disease patients given the intimate association of cardiovascular and kidney function."

ShowHide Related Items >><<
RNLX Renalytix
$23.22 /

+0.57 (+2.52%)

RNLX Renalytix
$23.22 /

+0.57 (+2.52%)

10/04/21 Guggenheim
Renalytix initiated with a Buy at Guggenheim
07/02/21 Berenberg
Renalytix AI initiated with a Buy at Berenberg
04/22/21 Investec
Renalytix AI upgraded to Buy from Hold at Investec
04/08/21 Stifel
Renalytix presented survey suggests favorable view on KidneyIntelX, says Stifel
RNLX Renalytix
$23.22 /

+0.57 (+2.52%)

Hot Stocks
Renalytix partners with St. Joseph's for value-based kidney health » 07:43
11/09/21
11/09
07:43
11/09/21
07:43
RNLX

Renalytix

$22.65 /

-0.35 (-1.52%)

St. Joseph's Health…

St. Joseph's Health and Renalytix announced a partnership to implement an advanced clinical care model designed to improve kidney health in patients with type 2 diabetes and early-stage chronic kidney disease. The Renalytix KidneyIntelX platform will be integrated with St. Joseph's Health care management to help prevent patients with diabetes and early-stage kidney disease from unnecessarily progressing to significant disease and/or kidney failure. KidneyIntelX is designed to enable primary care and specialist physicians to easily understand risk and implement St. Joseph's Health medication management, nutrition and education intervention protocols on a timely basis.

ShowHide Related Items >><<
RNLX Renalytix
$22.65 /

-0.35 (-1.52%)

RNLX Renalytix
$22.65 /

-0.35 (-1.52%)

10/04/21 Guggenheim
Renalytix initiated with a Buy at Guggenheim
07/02/21 Berenberg
Renalytix AI initiated with a Buy at Berenberg
04/22/21 Investec
Renalytix AI upgraded to Buy from Hold at Investec
04/08/21 Stifel
Renalytix presented survey suggests favorable view on KidneyIntelX, says Stifel
RNLX Renalytix
$22.65 /

-0.35 (-1.52%)

Over a month ago
Earnings
Renalytix reports FY21 EPS (43c) vs (16c) last year » 07:15
10/21/21
10/21
07:15
10/21/21
07:15
RNLX

Renalytix

$26.35 /

+1.78 (+7.24%)

Reports FY21 revenue…

Reports FY21 revenue $1.491M, one estimate $2M.

ShowHide Related Items >><<
RNLX Renalytix
$26.35 /

+1.78 (+7.24%)

RNLX Renalytix
$26.35 /

+1.78 (+7.24%)

10/04/21 Guggenheim
Renalytix initiated with a Buy at Guggenheim
07/02/21 Berenberg
Renalytix AI initiated with a Buy at Berenberg
04/22/21 Investec
Renalytix AI upgraded to Buy from Hold at Investec
04/08/21 Stifel
Renalytix presented survey suggests favorable view on KidneyIntelX, says Stifel
RNLX Renalytix
$26.35 /

+1.78 (+7.24%)

Hot Stocks
Renalytix launching KidneyIntelX in Veterans Health Administration hospitals » 07:07
10/07/21
10/07
07:07
10/07/21
07:07
RNLX

Renalytix

$20.48 /

-0.07 (-0.34%)

Renalytix announced the…

Renalytix announced the expansion of its commercial strategy to address early-stage kidney disease in the Veterans Health Administration patient population with the appointment of Jed Fulk to the position of Vice President Sales, Government Accounts. Mr. Fulk is developing and leading a team expected to grow to 42 regional sales managers and account executives during calendar year 2022 to support KidneyIntelX rollout to the VA Health System. KidneyIntelX will be deployed to help VA primary care physicians to identify diabetic kidney disease patients at high and low risk for rapid progression and kidney failure.

ShowHide Related Items >><<
RNLX Renalytix
$20.48 /

-0.07 (-0.34%)

RNLX Renalytix
$20.48 /

-0.07 (-0.34%)

10/04/21 Guggenheim
Renalytix initiated with a Buy at Guggenheim
07/02/21 Berenberg
Renalytix AI initiated with a Buy at Berenberg
04/22/21 Investec
Renalytix AI upgraded to Buy from Hold at Investec
04/08/21 Stifel
Renalytix presented survey suggests favorable view on KidneyIntelX, says Stifel
RNLX Renalytix
$20.48 /

-0.07 (-0.34%)

Initiation
Renalytix initiated with a Buy at Guggenheim » 06:38
10/04/21
10/04
06:38
10/04/21
06:38
RNLX

Renalytix

$20.92 /

+0.875 (+4.37%)

Guggenheim analyst David…

Guggenheim analyst David Westenberg initiated coverage of Renalytix AI with a Buy rating and $28 price target.

ShowHide Related Items >><<
RNLX Renalytix
$20.92 /

+0.875 (+4.37%)

RNLX Renalytix
$20.92 /

+0.875 (+4.37%)

07/02/21 Berenberg
Renalytix AI initiated with a Buy at Berenberg
04/22/21 Investec
Renalytix AI upgraded to Buy from Hold at Investec
04/08/21 Stifel
Renalytix presented survey suggests favorable view on KidneyIntelX, says Stifel
03/02/21 Investec
Renalytix AI downgraded to Hold from Buy at Investec
RNLX Renalytix
$20.92 /

+0.875 (+4.37%)

Hot Stocks
Mount Sinai initiates system-wide scale-up of Renalytix KindeyIntelX » 07:06
09/14/21
09/14
07:06
09/14/21
07:06
RNLX

Renalytix

$22.92 /

-0.33 (-1.42%)

Renalytix and the Mount…

Renalytix and the Mount Sinai Health System announced scaled-up implementation of the KidneyIntelX early-stage risk assessment testing and care management program across primary care and specialty clinician networks under a real-world evidence development program for patients with diabetic kidney disease. KidneyIntelX enables a shift in focus from care coordination efforts focused on Mount Sinai's late-stage kidney disease patients to a focus on patients with early stages of the disease where prognosis and treatment with population health care navigation assistance can improve patient care and outcomes and generate cost savings. Before the end of 2021, Mount Sinai expects to provide KidneyIntelX testing and downstream care management at a rate of 300 patients per week with approximately 6,000 eligible patients tested by calendar Q2 2022 under this development program. In an initial rollout across seven primary care practices in Manhattan, New York City, the KidneyIntelX program has demonstrated value for clinical care delivery by identifying patients with DKD at low, intermediate, and high risk of declining kidney function or kidney failure early in the disease lifecycle when treatment has the potential for maximum effect. "Our KidneyIntelX enabled diabetic kidney disease program allows us to provide a high standard of care in early-stage kidney disease patients where we have the best chance to help patients avoid significant kidney damage," said Robert Fields, MD, MHA, Executive Vice President and Chief Population Health Officer at Mount Sinai Health System. "Ongoing analysis and sharing of doctor and patient user experience combined with population level data insights is helping to drive systemwide access to early-stage risk-assessment and treatment."

ShowHide Related Items >><<
RNLX Renalytix
$22.92 /

-0.33 (-1.42%)

RNLX Renalytix
$22.92 /

-0.33 (-1.42%)

07/02/21 Berenberg
Renalytix AI initiated with a Buy at Berenberg
04/22/21 Investec
Renalytix AI upgraded to Buy from Hold at Investec
04/08/21 Stifel
Renalytix presented survey suggests favorable view on KidneyIntelX, says Stifel
03/02/21 Investec
Renalytix AI downgraded to Hold from Buy at Investec
RNLX Renalytix
$22.92 /

-0.33 (-1.42%)

Over a quarter ago
Hot Stocks
Renalytix AI appoints Daniel Levangie to board of directors » 07:06
08/30/21
08/30
07:06
08/30/21
07:06
RNLX

Renalytix

$26.96 /

+1.33 (+5.19%)

Renalytix announced the…

Renalytix announced the appointment of Daniel Levangie to the Company's board of directors. Levangie is also appointed as a member of the Company's remuneration committee. Levangie is co-founder and manager of ATON Partners, a private investment firm, and president and CEO of CereVasc.

ShowHide Related Items >><<
RNLX Renalytix
$26.96 /

+1.33 (+5.19%)

RNLX Renalytix
$26.96 /

+1.33 (+5.19%)

07/02/21 Berenberg
Renalytix AI initiated with a Buy at Berenberg
04/22/21 Investec
Renalytix AI upgraded to Buy from Hold at Investec
04/08/21 Stifel
Renalytix presented survey suggests favorable view on KidneyIntelX, says Stifel
03/02/21 Investec
Renalytix AI downgraded to Hold from Buy at Investec
RNLX Renalytix
$26.96 /

+1.33 (+5.19%)

Hot Stocks
Renalytix AI announces publication of results from budget impact analysis » 07:05
08/26/21
08/26
07:05
08/26/21
07:05
RNLX

Renalytix

$23.51 /

-0.84 (-3.45%)

Renalytix announced the…

Renalytix announced the publication of results from an external chronic kidney disease budget impact analysis projecting 5-year savings of $1.1 billion for a population of 100,000 patients with type 2 diabetes and chronic kidney disease tested with the Renalytix KidneyIntelX testing solution. Savings were driven by more effective pharmacy management and appropriate specialist referral compared to current standard of care for patients at high risk for disease progression and kidney failure.The detailed clinical and cost analysis concluded that health systems and insurance plans would realize these significant cost savings based on slowed disease progression, delayed, or prevented dialysis and transplants, and reduced dialysis crashes. Given the costs associated with current standard of care, the addition of an actionable bioprognostic approach to predict kidney function decline in T2DKD patients, stages 1-3b resulted in a projected 5-year savings of $1.1 billion associated with KidneyIntelX. Budget impact analysis is a key element in securing payer coverage in the U.S. market. BIA is an economic assessment that estimates the financial consequences of adopting a new, high value intervention like KidneyIntelX. The analysis takes a payer's perspective to evaluate whether a new intervention is affordable. It uses a short-term time horizon, up to 5 years. The model analyzes the direct costs of specific resources needed to implement KidneyIntelX informed care in the PCP office with savings associated with changes in care delivery. That result is multiplied by the number of people affected by the intervention. The results of the analysis provide an understanding of the total budget required to provide the intervention. The size of the population is explicitly considered for this analysis. The focus of a BIA is the direct costs of specific resources needed to put the intervention into effect, such as testing, pharmacy management, and specialist care. Consistent with best practices, sensitivity analyses were conducted to evaluate the impact of core assumptions related to physician compliance and disease progression. Renalytix will further expand its health economic and utility evidence through separate cost-effectiveness analyses evaluating whether intervention with KidneyIntelX testing provides value, defined as cost relative to health outcome, relative to current standard of care. These analyses will be completed in conjunction with three large real-world evidence studies with Mount Sinai Health System, Wake Forest/Atrium Health and University of Utah Health. The budget impact model was developed in collaboration with Boston Healthcare Associates, an external firm, in accordance with the International Society for Pharmacoeconomics and Outcomes Research good practices. BHA researchers evaluated the budget impact of management using KidneyIntelX as compared with standard of care over a 5-year horizon in patients with diabetic kidney disease. Results are detailed in, "Payer Budget Impact of an Artificial Intelligence In Vitro Diagnostic to Modify Diabetic Kidney Disease Progression," published in the Journal of Medical Economics.

ShowHide Related Items >><<
RNLX Renalytix
$23.51 /

-0.84 (-3.45%)

RNLX Renalytix
$23.51 /

-0.84 (-3.45%)

07/02/21 Berenberg
Renalytix AI initiated with a Buy at Berenberg
04/22/21 Investec
Renalytix AI upgraded to Buy from Hold at Investec
04/08/21 Stifel
Renalytix presented survey suggests favorable view on KidneyIntelX, says Stifel
03/02/21 Investec
Renalytix AI downgraded to Hold from Buy at Investec
RNLX Renalytix
$23.51 /

-0.84 (-3.45%)

Hot Stocks
Renalytix AI appoints Ann Berman to board of directors » 07:10
07/28/21
07/28
07:10
07/28/21
07:10
RNLX

Renalytix

$32.48 /

+1.53 (+4.94%)

Renalytix announced the…

Renalytix announced the appointment of Ann Berman to its board of directors. She will chair the board's audit committee and serve as member of the nomination committee. Preceding her retirement in 2009, Ms. Berman served as chief financial officer of Harvard University.

ShowHide Related Items >><<
RNLX Renalytix
$32.48 /

+1.53 (+4.94%)

RNLX Renalytix
$32.48 /

+1.53 (+4.94%)

07/02/21 Berenberg
Renalytix AI initiated with a Buy at Berenberg
04/22/21 Investec
Renalytix AI upgraded to Buy from Hold at Investec
04/08/21 Stifel
Renalytix presented survey suggests favorable view on KidneyIntelX, says Stifel
03/02/21 Investec
Renalytix AI downgraded to Hold from Buy at Investec
RNLX Renalytix
$32.48 /

+1.53 (+4.94%)

Hot Stocks
Renalytix AI appoints Joseph Hutson Vice President Global Quality, Regulation » 07:31
07/22/21
07/22
07:31
07/22/21
07:31
RNLX

Renalytix

$30.36 /

+1.95 (+6.86%)

Renalytix announced the…

Renalytix announced the appointment of Joseph Hutson as its Vice President of Quality and Regulatory. Hutson brings 23 years of experience in the life sciences industry. He will lead teams focused on assuring compliance with United States and international Quality Management System regulations and standards and driving efficient approval for a series of products under the KidneyIntelX brand through review by the appropriate regulatory authorities including the United States Food and Drug Administration and the European Medicines Agency, and other country specific regulatory bodies. Most recently, at Abbott Molecular Diagnostics, Hutson led Quality, Global and Clinical Compliance and he played a role in the rapid development, FDA Emergency Use Authorizations, manufacturing scale up and global distribution of 50M COVID-19 diagnostic tests throughout the world.

ShowHide Related Items >><<
RNLX Renalytix
$30.36 /

+1.95 (+6.86%)

RNLX Renalytix
$30.36 /

+1.95 (+6.86%)

07/02/21 Berenberg
Renalytix AI initiated with a Buy at Berenberg
04/22/21 Investec
Renalytix AI upgraded to Buy from Hold at Investec
04/08/21 Stifel
Renalytix presented survey suggests favorable view on KidneyIntelX, says Stifel
03/02/21 Investec
Renalytix AI downgraded to Hold from Buy at Investec
RNLX Renalytix
$30.36 /

+1.95 (+6.86%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.